Call a friend Grok (@runlolarn) profile picture

Struggling to be away from twitter & yet to succeed.

Alberta, Canada
Joined September 2013
Photo by Call a friend Grok (@runlolarn)Photo by Call a friend Grok (@runlolarn)Photo by Call a friend Grok (@runlolarn)Photo by Call a friend Grok (@runlolarn)Photo by Call a friend Grok (@runlolarn)Photo by Call a friend Grok (@runlolarn)Photo by Call a friend Grok (@runlolarn)
Before panicking over Adam Feuerstein’s tweets predicting a $CAPR rejection on Friday, look at his exact wording through a behavioral & linguistic lens. His word choices reveal three critical things: Zero Inside Leak (The Sourcing Tell): When reporters have an inside FDA scoop, they use phrases like "sources familiar" or "hearing chatter." Instead, AF points strictly to "the FDA review" (July’s public briefing docs) and says "I expect." That proves he has zero inside access to CBER's current file—he's just guessing off old public documents. Stuck in July ("Temporal Freezing"): By calling all data "post hoc" and "not persuasive," his vocabulary completely ignores everything that happened after July: CBER Biostats Head Dr. John Scott confirming SAP 3.0 was locked before unblinding, CBER accepting the 24-month data as a Major Amendment, $CAPR narrowing its label to upper-limb function (PUL 2.0), and 28 of 29 trial doctors who actually treated these boys writing to the FDA urging approval. Talking Tough for Clicks: Short, blunt one-word replies ("Incorrect") make him sound 100% certain so people react and share. If the FDA approves $CAPR anyway, it costs him nothing—he simply shifts to criticizing the FDA for lowering its standards, just like he did when Sarepta’s Duchenne drugs were approved. Bottom line: Unlike a CEO who talks directly with the FDA or the 28 trial doctors who saw patients improve firsthand, AF is reading the exact same public paperwork you are—and making a personal bet that old-school stats beat rare-disease flexibility.
3
1
20
1,879
I ran a forensic linguistic and behavioral breakdown on CEO Linda Marbán’s Q3 earnings call ahead of $CAPR’s Nov 22 FDA decision. Looking at her exact wording, tone, and rhythm reveals three major clues: Relaxed Q&A Rhythm (Zero Panic): Her prepared script was tight and lawyer-vetted, but in live Q&A she relaxed and joked ("I am being a little silly... right now, we are thinking we are done"). CEOs facing a hostile FDA fight or imminent CRL don't crack jokes 12 days out—it signals the review file is quiet and complete. The "Labeling" Word Choice: When asked if heart data makes the label, she didn't say "we haven't discussed a label." She said "we are not disclosing the label information at this point"—and added whether cardiac is "in the label now or a future label expansion," signaling that a narrow upper-limb (PUL 2.0) label is the primary path. Actions Speak Louder Than Legal Hedges: She used standard legal disclaimers ("if and when," "lucky enough"), yet $CAPR ramped Q3 spending to $44.7M to build patient support and payer access for a solo launch. No CEO can guarantee an FDA signature, but every behavioral tell says the review reached the finish line cleanly.
2
1
26
2,107
$CAPR is pulling back today alongside the broader biotech sector after the SMMT FDA rejection. Adam Feuerstein might think it’s because of his Sunday tweets, but anyone looking at the actual facts knows those are worlds apart: SMMT (Lung Cancer): Treated a large cancer market with existing options, and missed its main goal—proving patients actually lived longer. $CAPR : A fatal rare pediatric disease with ZERO approved treatments for arm function. Backed by positive pre-unblinding upper-limb data, 24-month crossover proof, and 28/29 doctors urging approval. Let's hope AF already has his face-saving tweets drafted for when CBER approves $CAPR, just like he had to scramble after Sarepta's Duchenne approvals. Biotech Twitter hasn't forgotten how sure—and how wrong—he was then. History and nature repeats. @statnews @adamfeuerstein
1
19
1,288
People are overcomplicating $CAPR ahead of the Nov 22 FDA decision. Look at the simple facts from the Q3 call: As per PDUFA VII rules, if the FDA finds any major new problems with a drug's data, safety, or factory during the final stretch of a review, they are expected to flag those roadblocks to the company before making their final decision. Yet heading into the final week: CEO Linda Marbán confirmed the FDA "have the data that they seem to need, and we haven't heard anything [further]." No new red flags or surprises popped up at the finish line. The July site inspection is completely closed with zero follow-up questions. No extra factory inspections are planned before Nov 22.
1
21
1,845
In a relentlessly progressive disease like DMD, where lost function may never return, how should the FDA balance statistical uncertainty against the ethical cost of denying access to a potentially beneficial treatment? July's 3–9 AdCom vote concerned cardiomyopathy, NOT upper-limb function. Since then, the FDA has accepted a Major Amendment reviewing 24-month HOPE-3 data and a narrower upper-limb indication. Physician advocacy, patient preferences, published research and the FDA's rare-disease flexibility all deserve consideration—not as substitutes for evidence, but as part of the totality of evidence. If further placebo-controlled trials are ethically difficult, should approval with rigorous postmarketing obligations be considered? I'm not arguing that $CAPR must be approved. I'm asking whether the cost of waiting deserves as much scrutiny as the risk of approving.
3
15
1,035
Checkmate Beyond $CAPR & Replimune, Checkmate also represents Biohaven, with official filings explicitly citing advocacy for rare-disease patients before FDA, HHS and the White House. Even more interesting: the same three lobbyists appear on the CAPR, Replimune and Biohaven filings. This is more than a one-off biotech engagement. It's an established channel for rare-disease policy advocacy. You can explore more of Checkmate on internet.
2
7
608
$CAPR A timely message from FDA leadership. On Nov. 10, FDA Acting Commissioner Kyle Diamantas published “Delivering Answers and Hope for Rare Disease Families,” highlighting a new regulatory framework shaped by 75 rare-disease community voices. In his words, see link below " Yet, despite these advancements, nearly 95 percent of rare disease patients still lack an approved treatment option. We must and can do better." 28 DMD investigators have also spoken and also long-term data are now before FDA. Nov. 22 become a defining moment for FDA's evolving rare disease philosophy. fda.gov/news-events/fda-voic…
10
651
Fascinating developments in 24 hours. Shorts run. $CAPR surges 26% on 10M shares. Linda confidently fields questions on labeling, commercialization to the extent on cardiomyopathy . JonesTrading upgrades to Buy ($25 PT), despite assigning just 35% odds of approval. The market seems more willing to embrace the upside than the analysts' probabilities suggest. Now add Capricor's reported $110K engagement with Checkmate Government Relations, which also represented Repl. More upgrades may be coming in morning. Shorts run Is management leaving no stone unturned while Wall Street underestimates FDA flexibility in rare diseases.
1
6
1,711
$CAPR Perhaps the most overlooked moment in Linda’s Q&A: “We’re not disclosing the label information at this point.” Interesting choice of words, just 12 days before PDUFA. If FDA and Capricor are already in substantive labeling negotiations, that could be an encouraging signal. Not confirmation of approval—but worth watching.
2
3
25
2,522
$CAPR earnings call Q&A: An interesting observation. Joe Pantginis of H.C. Wainwright, previously skeptical of FDA approval, focused on commercialization, NS Pharma and future opportunities—not CRL concerns. Just 12 days before PDUFA, could even skeptics be reconsidering? Perhaps the conversation is shifting from rejection risk to approval potential. Let's see if Joe follows up too with an upgrade tomorrow. Some one is going to get hurt shorting. My intuition.
4
705
Analyst Leland of Oppenheimer, who has a $54 price target on $CAPR,till yesterday in Tipranks, asked Linda an important question during the earnings call. He was looking beyond the Nov. 22 PDUFA decision: Could deramiocel, if given to younger DMD patients before heart damage develops, prevent scarring and delay cardiomyopathy? (HOPE-3 suggests a benefit in existing cardiac disease, but prevention remains unproven.) Leland wasn't just discussing approval. He was exploring deramiocel's much larger long-term opportunity—moving from slowing established heart disease to potentially preventing it. And she said we need to do more studies to do that. In my gut feeling many new upgrades will be coming in the morning.
2
15
1,420
Is Adam Feuerstein enjoying the increased X exposure. $CAPR . If the FDA rejects, he becomes the "I told you so" hero. Predicting failure in biotech is hardly a low-probability bet. But if the FDA approves it, he has already has his ego defense mechanism script ready which he played on Sarepta approval. His latest argument is that Dr. Craig McDonald's public letter from 28 HOPE-3 physicians urging approval proves Capricor knows its application is in trouble. But public letters from trial investigators are common in rare diseases with high unmet medical needs. McDonald is a Capricor consultant who presented at the AdCom, so his advocacy is hardly surprising. Making the letter public near the PDUFA date could reflect patient advocacy, media strategy, or an attempt to influence regulators. None necessarily means "we know we're in trouble." Similar letters have accompanied both approvals and rejections.(LIke his other critics i also stay blocked by adam hence it is a separate post.) @grok, please assess this independently: Is Adam presenting evidence of an impending rejection, or interpreting an ordinary advocacy effort to fit his bearish prediction?
2
19
1,648
$CAPR Today's Good News. This upgrade still does not appear in Tip Ranks. (Tomorrow more upgrades maycome. May skyrocket.) This is what AI said analyzing this conversation of Linda with Oppenheimer. Oppenheimer upgrades Capricor to *Outperform with a $54 Price Target* following their deep-dive follow-up call with CEO Dr. Linda Marbán. 'The market is completely underestimating the strength of this BLA Major Amendment. What Linda Marbán Disclosed to Oppenheimer: 1️⃣ *82-Patient Dataset:* Submitted a massive 24-month HOPE-3 OLE cohort (82/106 patients retained = 77% completion rate). 2️⃣ *160-Page Robustness Rebuttal:* Filed a 160-page biostatistical package directly destroying the AdCom’s "efficacy fragility" ($p \approx 0.21$) arguments. 3️⃣ *Direct Senior FDA Talks:* Interactions are happening directly with high-ranking CBER leadership (not just rank-and-file staff) to align on the upper-limb label. 4️⃣ *Pre-PDUFA Data Drop:* Capricor confirmed it will disclose the 24-mo HOPE-3 OLE curves to the public *BEFORE* the Nov 22 PDUFA date (likely fall congresses). 🎯 *Bottom Line:* CRL risk averted. High-powered dataset in hand. New PDUFA: *Nov 22, 2026*.' ca.investing.com/news/stock-…
2
1
14
1,707
$capr When I found that lawyers from both sides met on Aug 7th, I got it analyzed from AIs. The briefest takeaway is that the chance of an immediate CRL on Aug 22 is near zero for clear procedural reasons: * *Top Counsel on the Record:* The FDA’s public logs show FDA’s Chief Counsel met with Latham & Watkins (representing Capricor) on Aug 7. * *Process Over P-Values:* Elite counsel meets FDA legal leadership to secure *due process and procedural review pathways*, not to debate clinical curves. * *AdCom Scope Clarified:* The 9–3 vote was strictly on secondary heart function, leaving the primary arm function (PUL 2.0) endpoint (The Lancet) unadjudicated by the panel. * *Statutory 3-Month Extension (21 CFR § 601.2):* Because FDA requested long-term data on May 14, submitting the 24-month OLE Major Amendment legally requires CBER to review the package and extend the PDUFA clock by 90 days rather than issuing an immediate CRL. *Takeaway:* Procedural alignment secured the review extension to late November. The final decision then shifts back to the science: the strength of the 24-month data and placebo crossover curves.
1
20
1,590